More importantly, EGFR and HER2 are currently important therapeutic targets in many types of cancers, and several types of small molecule HER tyrosine kinase inhibitors or monoclonal antibodies against the EGFR and HER2 have already been approved for the treatment of patients with a wide range of human cancer [38,39,40,41,42,43]. Here, ERBB2 is linked to cancer.